Tenet Healthcare director James Bierman sells $1.22m in stock By Investing.com

James L. Bierman, a director at Tenet Healthcare Corp. (), sold 5,000 shares of the company’s common stock on July 27, 2026. The transactions totaled $1,224,800, with shares sold at a weighted average price of $244.96 each.

The shares were sold in multiple transactions at prices ranging from $244.95 to $245.29. The timing of the sale comes as Tenet Healthcare stock trades near its 52-week high of $262.68, having delivered a remarkable 68% return over the past year with a current P/E ratio of 9.97.Following these sales, Mr. Bierman directly owns 31,604 shares of Tenet Healthcare common stock. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive Pro Research Reports covering THC and 1,400+ other US equities on the platform.

In other recent news, Tenet Healthcare reported impressive second-quarter 2026 results, surpassing Wall Street expectations. The company announced adjusted earnings of $6.12 per share on revenue of $5.63 billion, significantly beating analysts’ predictions of $4.23 per share on $5.43 billion in revenue. Following this strong performance, Tenet Healthcare raised its full-year outlook. In response to these developments, several firms have adjusted their price targets for the company. Guggenheim increased its price target to $283, citing the hospital business strategy of focusing on high acuity, non-elective services. Raymond James also raised its target to $275, highlighting the company’s standout performance compared to other hospital operators. UBS set a new price target of $308, reflecting a higher earnings outlook due to incremental supplemental payments and process improvements. Additionally, Cantor Fitzgerald raised its target to $270, acknowledging Tenet’s ability to exceed investor expectations despite changes in the Florida Directed Payment Program.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.